On the Company sold for million and immediately leased back certain medical equipment in rental service to a party specializing in such transactions. The leaseback term is months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did qualify for the sale-leaseback accounting under ASC The medical equipment remains recorded on the accompanying condensed consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of was million.

 

On the Company and its primary lender entered into the amendment (the “Fifth Amendment”) to its existing credit facility (the “Credit Agreement”). Among other things, the Fifth Amendment amended the Credit Agreement to () increase our borrowing capacity under our existing equipment line to million, () revise the definition of earnings before interest, taxes, depreciation and amortization, a non-GAAP financial measure, to include additional add-back adjustments for the years ended or ending and () revise the definition of fixed charge coverage ratio for the year ending to include an unfinanced portion of capital expenditures of up to million for the year ending ) revise the Credit Agreement’s maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets and () revise the maximum leverage ratio for each of the quarters during and

 

As of the Company’s term loans and equipment line under its credit facility had balances of million and million, respectively. The net availability under the revolving credit line under the credit facility is based upon our eligible accounts receivable and eligible inventory and is computed as follows (in thousands):

 

		June 30,				December 31,
		2019				2018
Revolver:
Gross availability		$	11,000			$	9,973
Outstanding draws			-				-
Letters of credit			(1,750	)			(750	)
Landlord reserves			(71	)			(70	)
Net availability		$	9,179			$	9,153

 

The Company had future maturities of loans and other financing as of as follows (in thousands):

 

		2019				2020				2021				2022				2023 and thereafter				Total
Term Loan A		$	1,792			$	3,584			$	16,143			$	-			$	-			$	21,519
Term Loan C			921				1,229				5,529				-				-				7,679
Equipment Line			128				512				512				512				898				2,562
Unamortized value of the debt issuance costs			(20	)			(39	)			(39	)			-				-				(98	)
Other financing			301				652				725				222				-				1,900
Total		$	3,122			$	5,938			$	22,870			$	734			$	898			$	33,562

 

The following is a breakdown of the Company’s current and long-term debt as follows (in thousands):

 

June 30, 2019													December 31, 2018
		Current Portion				Long-Term Portion				Total					Current Portion				Long-Term Portion				Total
Term Loan A		$	3,584			$	17,935			$	21,519		Term Loan A		$	3,584			$	19,727			$	23,311
Term Loan C			1,536				6,143				7,679		Term Loan C			1,229				6,757				7,986
Equipment Line			384				2,178				2,562		Equipment Line			128				2,434				2,562
Unamortized value of debt issuance costs			(39	)			(59	)			(98	)	Unamortized value of debt issuance costs			(38	)			(76	)			(114	)
Other financing			619				1,281				1,900		Other financing			-				-				-
Total		$	6,084			$	27,478			$	33,562		Total		$	4,903			$	28,842			$	33,745

 

As of interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable -day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from to or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus in each case, plus a margin ranging from - to The actual rate at was (LIBOR of plus ). The actual CBFR Loan rate at was (lender’s prime rate of ).

 

As of the Company was in compliance with all debt-related covenants under the Credit Agreement.